KPV (Lys-Pro-Val)

Mechanism of Action

KPV (Lysine-Proline-Valine) is the C-terminal tripeptide of alpha-melanocyte-stimulating hormone (α-MSH). While α-MSH regulates pigmentation, appetite, and sexual function via MC1R–MC5R receptors, KPV specifically targets MC1R on immune cells — particularly intestinal epithelial cells and macrophages.

MC1R activation by KPV produces a cascade of anti-inflammatory effects:

• NF-κB inhibition — the master inflammatory transcription factor is downregulated
• Reduced pro-inflammatory cytokines — IL-1β, TNF-α, and IL-6 production suppressed
• Macrophage polarisation — shift from M1 (inflammatory) to M2 (repair) phenotype
• Gut epithelial protection — direct protective effects on intestinal lining cells

Unlike broadly immunosuppressive drugs, KPV's anti-inflammatory effects are relatively targeted to the melanocortin pathway, potentially reducing systemic immunosuppression risks.

Evidence in IBD Models

The strongest evidence for KPV comes from murine colitis models. Multiple studies demonstrate that KPV administered orally or via nanoparticle delivery significantly reduces colitis severity scores, histological inflammation, and inflammatory cytokine profiles in DSS-induced and IL-10 knockout mouse models of IBD. ^[]

A 2020 study demonstrated oral KPV nanoparticles accumulated preferentially in inflamed colon tissue — suggesting targeted gut delivery is achievable. ^[]

Human data: No published human RCTs exist as of 2026. All human use data is anecdotal from online communities and self-experimenters.

Oral vs. Subcutaneous

Oral (encapsulated): Preferred for gut-targeted inflammation. The peptide is partially degraded in the stomach but enough reaches the intestinal lining for local effects. Enteric-coated capsules may improve delivery.

Subcutaneous: Provides systemic KPV levels for broader anti-inflammatory effects beyond the gut. Used for systemic inflammatory conditions.

The Gut Barrier Protocol

The combination of BPC-157 + KPV addresses gut repair comprehensively: BPC-157 rebuilds mucosal structure and promotes angiogenesis; KPV suppresses the inflammatory environment that prevents healing. This synergy represents one of the most rational peptide stacks for leaky gut, post-antibiotic dysbiosis, and IBD management.